Dyne Therapeutics, Inc. (DYN)
Dyne Therapeutics develops drug candidates for genetic neuromuscular diseases using its FORCE delivery platform. It last closed at $16.02 on Nov 17, down 4.07% on the day. The average 12-month price target from 7 analysts is $28.00 (+74.8% from the last close), with a high of $47.00 and a low of $10.00. Analyst consensus is Buy, based on the latest ratings from 7 firms (6 buy, 0 hold, 1 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in DYN, 100% of them bullish and 0% bearish. In the past 30 days there were 4 dark pool prints totaling $3.3M, the largest $928K.
Key Stats
Last 12 monthsNot reported for this period.
From DYN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 7 analysts who set a price target on DYN in the past 90 days. The average target is $28.00, with a high of $47.00 and a low of $10.00, compared with the last close of $16.02.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 28 | Oppenheimer | Downgrade | Buy | $15 |
| Sep 30 | HC Wainwright & Co. | Maintained | Buy | $32 |
| Sep 29 | Piper Sandler | Reiterated | Buy | $47 |
| Sep 9 | Morgan Stanley | Target lowered | Buy | $45 → $36 |
| Sep 9 | JP Morgan | Downgrade | Sell | $10 |
Technical Analysis
The stock is 7% below its 20 day and 4% below its 50 day average. It is 20% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 42). The nearest support is the Pivot S1 at $15.68, and the nearest resistance the Pivot at $16.26.
| RSI (14) | 41.93 | Middle of its range | Neutral |
| MACD | 0.01 | Below its signal line | Bearish |
| Stochastic | 22.5 | Middle of its range | Neutral |
| ADX (14) | 20.2 | Weak trend | |
| Williams %R | -96.8 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -75.7 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −11.3% | Change over 10 sessions | Bearish |
| ATR (14) | $0.93 | Typical daily range, 5.8% of price |
| RSI (14) | 42.02 | Middle of its range | Neutral |
| MACD | -1.05 | Below its signal line | Bearish |
| Stochastic | 22.6 | Middle of its range | Neutral |
| ADX (14) | 24.8 | Weak trend | |
| Williams %R | -85.3 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -66.2 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −12.0% | Change over 10 sessions | Bearish |
| ATR (14) | $2.39 | Typical daily range, 14.9% of price |
What happened before
See how DYN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How DYN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in DYN in the last 90 days.
Dark Pool
30DDYN Institutional Ownership
Full report →- ▲185 buying vs 95 selling
- ▲Held by funds +12.2 pts
- ▲Funds holding +22
- ▲Superinvestors: 3 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 269 | 247 | +8.9% |
| In funds' top 10 | 5 | 4 | +25.0% |
| Held by funds | 114.0% | 101.8% | +12.2 pts |
| New / increased | 59 / 126 | 45 / 89 | +38.1% |
| Reduced / sold out | 60 / 35 | 75 / 29 | −8.7% |
| Put/call ratio | 0.22 | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DYN is in one of them and how their past DYN trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered DYN in an article yet. Here's the latest on the wider market.
About Dyne Therapeutics
Dyne Therapeutics is a biotechnology company based in Waltham, Massachusetts, that develops drug candidates for muscle diseases caused by genetic changes. Its FORCE platform attaches a payload, such as an oligonucleotide or enzyme, to an antibody fragment that binds to a receptor found on muscle cells, aiming to carry treatments to muscle tissue and the central nervous system. The company's candidates target conditions including Duchenne muscular dystrophy, myotonic dystrophy type 1, facioscapulohumeral dystrophy and Pompe disease. Its candidates are still in clinical trials and not yet sold, with patients as the intended end users.
- Headquarters
- Waltham, MA



